Kortikobazal Dejenerasyon: Tanıdan Tedaviye Güncel ve Bütüncül Bir Bakış

Ali F, Josephs KA. Corticobasal degeneration: key emerging issues. J Neurol. 2018; 265(2):439-445.

Grijalvo-Perez AM, Litvan I. Corticobasal degeneration. Semin Neurol. 2014; 34(2):160-73.

Saranza GM, Whitwell JL, Kovacs GG et al. Corticobasal degeneration. Int Rev Neurobiol. 2019; 149:87-136.

Révész T, Lees AJ, Morris R H. Corticobasal degeneration: An update. Ideggyogy Sz. 2024; 30;77(11-12):379-394.

Lyons S, Trépel D, Lynch T et al. The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis. J Neurol. 2023; 270(9):4451-4465.

Wenning GK, Litvan I, Jankovic J et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998; 64(2):184-9.

Constantinides VC, Paraskevas GP, Paraskevas PG et al. Corticobasal degeneration and corticobasal syndrome: A review. Clin Park Relat Disord. 2019; 1:66-71.

Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998; 55(7):957-61.

Murray R, Neumann M, Forman MS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007; 17;68(16):1274-83.

Witman GB, Cleveland DW, Weingarten MD, et al. Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A. 1976; 73(11):4070-4.

Ling H, Kovacs GG, Vonsattel JP et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016; 139(12):3237-3252.

Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999; 11;53(4):795-800.

Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016; 22 Suppl 1(0 1): S29-33.

Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. J Neuroinflammation. 2017; 09;14(1):118.

Ferrer I, López-González I, Carmona M et al. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol. 2014; 73(1):81-97.

Murray ME, Kouri N, Lin WL et al. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther. 2014; 6(1):1.

Dickson DW, Bergeron C, Chin SS et al,.Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002; 61(11):935-46.

Koga S, Josephs KA, Aiba I et al. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022; 13;93(9):919-29.

Kouri N, Ross OA, Dombroski B et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015; 16; 6:7247.

Robinson JL, Yan N, Caswell C et al. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. J Neuropathol Exp Neurol. 2020; 01;79(3):296-304.

Forrest SL, Kril JJ, Stevens CH et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.

Brain. 2018; 01;141(2):521-534.

Ghetti B, Oblak AL, Boeve BF et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015; 41(1):24-46.

Yokoyama JS, Karch CM, Fan CC et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017; 133(5):825-837.

Broce I, Karch CM, Wen N, et al. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med. 2018; 15(1): e1002487.

Fekete R, Bainbridge M, Baizabal-Carvallo JF et al. Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat Disord. 2013; 19(11):1049-52.

Hassan A, Whitwell JL, Boeve BF. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord. 2010;16(3):208–214. doi: 10.1016/j.parkreldis.2009.11.013.

Stamelou M, Alonso-Canovas A, Bhatia KP. Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov Disord. 2012;27(6):696–702. doi: 10.1002/mds.24992.

Notturno F, Zappasodi F, Maruotti V et al. Cortical origin of myoclonus in early stages of corticobasal degeneration. Mov Disord. 2011;26(8):1567–1569. doi: 10.1002/mds.23612.

Pharr VL, Uttl B, Stark M et al. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2001;56(7):957–963. doi: 10.1212/wnl.56.7.957.

Soliveri P, Piacentini S, Girotti F. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2005;64(3):448–453. doi: 10.1212/01.WNL.0000150900.90592.3D.

Constantinides VC, Paraskevas GP, Potagas C et al. Quantifying apraxia and oculomotor abnormalities in patients with atypical parkinsonism: a new avenue for differential diagnosis? Parkinsonism Relat Disord. 2019; 61:39–44. doi: 10.1016/j.parkreldis.2018.12.006.

Bundick T Jr, Spinella M. Subjective experience, involuntary movement, and posterior alien hand syndrome. J Neurol Neurosurg Psychiatry. 2000;68(1):83–85. doi: 10.1136/jnnp.68.1.83.

Aboitiz F, Carrasco X, Schröter C, et al. The alien hand syndrome: classification of forms reported and discussion of a new condition. Neurol Sci. 2003;24(4):252–257. doi: 10.1007/s10072-003-0149-4.

Fitzgerald DB, Drago V, Jeong Y et al. Asymmetric alien hands in corticobasal degeneration. Mov Disord. 2007;22(4):581–584. doi: 10.1002/mds.21337.

Constantinides VC, Paraskevas GP, Paraskevas PG et al. Corticobasal degeneration and corticobasal syndrome: A review. Clin Park Relat Disord. 2019 Aug 30; 1:66-71. doi: 10.1016/j.prdoa.2019.08.005.

Armstrong MJ, Litvan I, Lang AE et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496-503.

Horie K, Barthélemy NR, Spina S et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022 Dec;28(12):2547-2554.

Mattsson N, Insel PS, Donohue M et al. Alzheimer’s Disease Neuroimaging Initiative. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May;72(5):554-60.

Whitwell JL, Jack CR, Boeve BF et al. Imaging correlates of pathology in corticobasal syndrome. Neurology. 2010 Nov 23;75(21):1879-87.

Carlos AF, Tosakulwong N, Weigand SD et al. Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Commun. 2022;4(3): fcac108.

Teune LK, Bartels AL, de Jong BM et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010 Oct 30;25(14):2395-404.

Niethammer M, Tang CC, Feigin A et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014 Nov;137(Pt 11):3036-46.

Pardini M, Huey ED, Spina S et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019 Mar 05;92(10): e1121-e1135.

Murugan NA, Chiotis K, Rodriguez-Vieitez E et al. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1369-1382.

Mena AM, Strafella AP. Imaging pathological tau in atypical parkinsonisms: A review. Clin Park Relat Disord. 2022; 7:100155.

Murugan NA, Nordberg A, Ågren H. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy. ACS Chem Neurosci. 2021 Jul 07;12(13):2437-2447.

Bluett B, Pantelyat AY, Litvan I et al. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Front Neurol. 2021; 12:694872.

van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 05;388(1):9-21.

Sims JR, Zimmer JA, Evans CD et al. TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 08;330(6):512-527.

Dam T, Boxer AL, Golbe LI et al. PASSPORT Study Group. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 Aug;27(8):1451-1457.

Khanna MR, Kovalevich J, Lee VM et al. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement. 2016 Oct;12(10):1051-1065.

VandeVrede L, Ljubenkov PA, Rojas JC et al. Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics. 2020 Oct;17(4):1563-1581.

Mummery CJ, Börjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023 Jun;29(6):1437-1447.

DeVos SL, Miller RL, Schoch KM et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017 Jan 25;9(374)